Amr Said Shalaby1, Abdullah Osama Bahanan1, Mishal Hasan Alshehri1, Khaled Ahmed Elag1. 1. Shalaby, MD, Eradah Complex for Mental Health and Addiction, Eradah Services, Jeddah, Saudi Arabia. Department of Neuropsychiatry, Menoufia University, Egypt. Bahanan, M.B.B.CH, Eradah Complex for Mental Health and Addiction, Eradah Services, Jeddah, Saudi Arabia. Alshehri, M.B.B.CH, Eradah Complex for Mental Health and Addiction, Eradah services, Jeddah, Saudi Arabia. Elag, MD, Eradah Complex for Mental Health and Addiction, Eradah Services, Jeddah, Saudi Arabia. Department of Neuropsychiatry, Ain Shams University, Egypt.
Abstract
Objectives: To explore the relationship between sleep deprivation and amphetamine-induced psychosis. Methods: The patient group included 78 patients with a diagnosis of amphetamine (Captagon)-induced psychosis. The control group included 49 patients with no current or past history of amphetamine (Captagon)-induced psychosis. All study subjects underwent the following: a demographic sheet, a structured clinical interview for SM-IV (SCID 1), a drug use questionnaire, a questionnaire to explore any relationship between sleep deprivation and Captagon-induced psychosis, routine medical investigation, and urine screening for detection of drugs. Results: The patient group showed significantly higher both regular and maximum daily doses of Captagon. Patients showed more periods of sleep deprivation with the use of Captagon in comparison to controls, especially with the increase of the Captagon dose. Patients believed that the occurrence and termination of sleep deprivation were the cause of the start and end of psychotic experiences (more so than the increase and decrease or stoppage of Captagon doses). Conclusion: sleep deprivation plays an essential role in the development of psychotic symptoms in patients who are using Captagon.
Objectives: To explore the relationship between sleep deprivation and amphetamine-induced psychosis. Methods: The patient group included 78 patients with a diagnosis of amphetamine (Captagon)-induced psychosis. The control group included 49 patients with no current or past history of amphetamine (Captagon)-induced psychosis. All study subjects underwent the following: a demographic sheet, a structured clinical interview for SM-IV (SCID 1), a drug use questionnaire, a questionnaire to explore any relationship between sleep deprivation and Captagon-induced psychosis, routine medical investigation, and urine screening for detection of drugs. Results: The patient group showed significantly higher both regular and maximum daily doses of Captagon. Patients showed more periods of sleep deprivation with the use of Captagon in comparison to controls, especially with the increase of the Captagon dose. Patients believed that the occurrence and termination of sleep deprivation were the cause of the start and end of psychotic experiences (more so than the increase and decrease or stoppage of Captagon doses). Conclusion: sleep deprivation plays an essential role in the development of psychotic symptoms in patients who are using Captagon.
Authors: J Michael Wilkerson; Syed W Noor; Jayson M Rhoton; Dennis Li; B R Simon Rosser Journal: Drug Alcohol Depend Date: 2018-08-15 Impact factor: 4.492
Authors: Kathleen M Grant; Tricia D LeVan; Sandra M Wells; Ming Li; Scott F Stoltenberg; Howard E Gendelman; Gustavo Carlo; Rick A Bevins Journal: J Neuroimmune Pharmacol Date: 2011-07-05 Impact factor: 4.147